HC Wainwright Analysts Boost Earnings Estimates for TRDA

Entrada Therapeutics, Inc. (NASDAQ:TRDA - Free Report) - Stock analysts at HC Wainwright increased their Q4 2024 earnings per share estimates for shares of Entrada Therapeutics in a report released on Wednesday, November 6th. HC Wainwright analyst R. Selvaraju now anticipates that the company will earn ($0.66) per share for the quarter, up from their previous forecast of ($0.67). HC Wainwright has a "Buy" rating and a $20.00 price objective on the stock. The consensus estimate for Entrada Therapeutics' current full-year earnings is $0.98 per share.

Separately, Oppenheimer upped their price target on shares of Entrada Therapeutics from $25.00 to $28.00 and gave the company an "outperform" rating in a report on Wednesday.

Entrada Therapeutics Trading Up 3.1 %

Entrada Therapeutics stock traded up $0.59 during mid-day trading on Friday, hitting $19.82. 239,326 shares of the company's stock were exchanged, compared to its average volume of 105,971. The stock has a market cap of $741.66 million, a P/E ratio of 12.47 and a beta of -0.26. The stock has a 50 day moving average of $16.40 and a two-hundred day moving average of $15.68. Entrada Therapeutics has a 1-year low of $10.75 and a 1-year high of $19.95.

Entrada Therapeutics (NASDAQ:TRDA - Get Free Report) last posted its earnings results on Tuesday, August 13th. The company reported $1.55 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.65 by $0.90. Entrada Therapeutics had a net margin of 25.53% and a return on equity of 16.11%. The firm had revenue of $94.69 million during the quarter, compared to analysts' expectations of $55.00 million.

Insider Activity

In other Entrada Therapeutics news, CFO Kory James Wentworth sold 3,195 shares of the company's stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $14.97, for a total value of $47,829.15. Following the completion of the transaction, the chief financial officer now owns 76,486 shares of the company's stock, valued at $1,144,995.42. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. In other news, insider Natarajan Sethuraman sold 2,642 shares of Entrada Therapeutics stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $15.09, for a total transaction of $39,867.78. Following the sale, the insider now directly owns 183,816 shares in the company, valued at approximately $2,773,783.44. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Kory James Wentworth sold 3,195 shares of the stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $14.97, for a total transaction of $47,829.15. Following the completion of the transaction, the chief financial officer now directly owns 76,486 shares of the company's stock, valued at $1,144,995.42. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 10,187 shares of company stock valued at $155,947. Insiders own 7.59% of the company's stock.

Institutional Investors Weigh In On Entrada Therapeutics

A number of institutional investors have recently added to or reduced their stakes in TRDA. Renaissance Technologies LLC acquired a new position in shares of Entrada Therapeutics in the 2nd quarter worth approximately $636,000. The Manufacturers Life Insurance Company raised its stake in Entrada Therapeutics by 3.9% during the second quarter. The Manufacturers Life Insurance Company now owns 57,098 shares of the company's stock worth $814,000 after acquiring an additional 2,146 shares in the last quarter. Acadian Asset Management LLC bought a new position in shares of Entrada Therapeutics during the first quarter valued at $79,000. Vanguard Group Inc. boosted its holdings in shares of Entrada Therapeutics by 1.3% in the 1st quarter. Vanguard Group Inc. now owns 1,078,908 shares of the company's stock worth $15,288,000 after acquiring an additional 13,742 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC grew its position in Entrada Therapeutics by 427.6% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 14,763 shares of the company's stock worth $209,000 after acquiring an additional 11,965 shares during the last quarter. 86.39% of the stock is owned by institutional investors and hedge funds.

About Entrada Therapeutics

Entrada Therapeutics, Inc, a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1.